Loading
Loading
Organ & Bioregulator Research · 20mg
Janoshik-tested · 10 vials per kit
Chonluten is a synthetic tripeptide bioregulator studied in preclinical research for its anti-inflammatory and tissue-regulatory effects. Research has examined its potential to inhibit TNF and IL-6 production, regulate cell proliferation and differentiation, and reduce oxidative stress. Studies have explored applications in COPD, asthma, and inflammatory gastrointestinal conditions.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Chonluten
T-34 Tripeptide
Chonluten is a synthetic tripeptide (T-34) developed as a bronchial and pulmonary bioregulator in the Khavinson research programme. It is studied for regulatory effects on respiratory epithelial tissue in the context of age-related decline and chronic pulmonary conditions.
As with other Khavinson short peptides, Chonluten is proposed to bind chromatin in target tissues — in this case bronchial epithelial and alveolar cells — modulating transcription of genes relevant to cell renewal, inflammatory response, and respiratory function. Anti-apoptotic and antioxidant effects have been described in bronchial cell models.
Preclinical studies indicate Chonluten may normalise cell renewal in aged bronchial epithelium and reduce inflammatory mediator production in respiratory challenge models. Research also includes pulmonary fibrosis and chronic obstructive conditions in aged animals.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
